 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- | bi-4SCAR CD19/22 T / SZGIMI
New P1/2 trial, CAR T-Cell Therapy: CD19/22 Bi-specific CAR-T Cell Therapy (clinicaltrials.gov) - Jun 26, 2022
P1/2, N=60, Recruiting, Sponsor: Shenzhen Geno-Immune Medical Institute